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Abstract
Background—Rotavirus vaccination of all infants began in the United States in 2006. While the 
effect of vaccination on childhood hospitalizations for rotavirus have been well described, the 
effects of rotavirus vaccine on ED visits are less well documented.
Methods—Using the State Emergency Department Databases (SEDD) for 10 US states, we 
compared rates of gastroenteritis- and rotavirus-coded ED visits among children < 5 years of age 
in pre-vaccine (2003–2006) with post-vaccine (2008–2013) years; 2007 was excluded as a 
transition year. We analyzed ED visit rates by age group, sex, race, and rotavirus season.
Results—The pre-vaccine annual gastroenteritis-coded ED visit rate among children < 5 years of 
age of 426 per 10,000 (annual range, 396–477 per 10,000) declined to 382 per 10,000 in post-
vaccine years, a 10.3% (±0.3%, p<.0001) rate reduction overall. Compared to pre-vaccine years, 
annual ED visit rates for gastroenteritis decreased by 6.5% (±0.6%) in 2008, 12.3% (±0.6%) in 
2010, 14.8% (±0.5%) in 2011, 20.4% (±0.5%) in 2012 and 10.1% (±0.6%) in 2013; a small 
increase of 1.8% (±0.6%) was seen in 2009 (p<.0001 for all individual comparisons). Declines 
were similar by sex and race and were greater in children <2 years of age (range 14.1–20.6%, p<.
0001) than older children (increase of 3.3% ± 0.6%, p<.0001). A decline of 21.2% (±0.4%, p<.
0001) in ED visits was seen during the rotavirus season months from January through June versus 
an increase of 9.5% (±0.6%, p<.0001) during July to December. ED visits specifically coded for 
rotavirus showed more prominent declines than for all gastroenteritis.
Conclusions—ED visits for gastroenteritis in US children have declined since introduction of 
rotavirus vaccine.
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Background
Prior to the introduction of rotavirus vaccine for all infants in the US in 2006, rotavirus 
gastroenteritis caused an estimated 205,000 – 272,000 emergency department (ED) visits 
annually among children under 5 years of age [1, 2]. Current US guidelines recommend 
either 2 doses of a monovalent rotavirus vaccine (RV1; Rotarix, GSK Biologicals) or 3 doses 
of a pentavalent rotavirus vaccine (RV5; Rotateq, Merck) for routine immunization of all US 
infants before the age of 8 months [1].
Since rotavirus vaccine introduction, there has been a dramatic decline in the burden of 
severe rotavirus disease in US children [3–8]. Moreover, rotavirus vaccination in infants 
offers indirect benefits by reducing rotavirus infection in older children and adults [9]. While 
the effect of vaccination on childhood hospitalizations for rotavirus has been well described, 
the effects of rotavirus vaccine on ED visits are less well documented. While rotavirus 
vaccination was approved primarily to reduce the risk of severe diarrhea (as measured by 
hospitalizations and deaths), an added benefit of vaccination would be reducing ED 
congestion through less diarrhea visits. Active surveillance through the New Vaccine 
Surveillance Network (NVSN) showed a 76% reduction in laboratory-confirmed rotavirus 
infection in ED visits in the first two seasons after vaccine introduction, but these data were 
limited to hospitals in three sentinel US counties [10]. A prior analysis using insurance 
databases showed a decrease in ED visits for gastroenteritis during the first four years of the 
vaccination program from 2008–2011 [5], but these data cannot be generalized to the entire 
US population.
With maturation of the rotavirus vaccine program, immunization coverage in children less 
than 3 years of age has increased from 44% in 2009 to 73% in 2013 [11]. We aim to provide 
a comprehensive evaluation of ED utilization among children <5 years of age for acute 
gastroenteritis through 2013 using robust and more nationally representative discharge data. 
We estimated baseline pre-vaccine burden and monitored trends in gastroenteritis- and 
rotavirus-coded ED visits among US children younger than 5 years in 10 US states over an 
11-year period to account for expected year-to-year variation in rotavirus trends [12].
Methods
Data Source
We analyzed data from the State Emergency Department Databases (SEDD) over an 11-year 
period (2003–2013). The SEDD is a component of the Healthcare Cost and Utilization 
Project (HCUP), produced by the Agency for Healthcare Research & Quality (AHRQ), and 
captures emergency visits at hospital-affiliated EDs [13]. SEDD files include all patients, 
regardless of payer. We restricted our analysis to ten states that continuously reported data to 
SEDD over the 11-year period: Connecticut, Georgia, Indiana, Maryland, Missouri, 
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Nebraska, South Carolina, Tennessee and Vermont. In 2013, there were 3,225,505 children 
under 5 years of age in these ten states, equal to about 16% of the total U.S. population 
under 5 years of age. Seven states - Georgia, Indiana, Maryland, Missouri, South Carolina, 
Tennessee and Vermont – consistently reported race information, and were included in 
analysis by racial groups.
Definition of Gastroenteritis & Rotavirus-Coded ED Visit
Gastroenteritis ED visits were identified with the use of the following International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 
diarrhea of determined etiology (bacterial [001–005 and 008.0–008.5, excluding 003.2]; 
parasitic [006–007, excluding 006.3–006.6]; and viral [008.6 and 008.8]), and diarrhea of 
undetermined etiology (presumed infectious [009.0–009.3] and presumed noninfectious 
[558.9 and 787.91]) [14]. Rotavirus-coded emergency department visits were a subset of 
gastroenteritis visits that included the specific ICD-9-CM code for rotavirus (008.61).
Demographic and Other Characteristics
Gastroenteritis- and rotavirus-coded ED visits among children < 5 years of age for years 
2003–2013 were examined by sex, month and year of visit, age group by month (0–2, 3–5, 
6–11, 12–23, and 24–59), and race. ED visits with missing information for a specific 
variable were excluded from analysis of that variable but were included for all other 
analyses.
Rate Calculations and Pre- and Post-vaccine Comparisons
ED visit rates were calculated by dividing the number of ED visits for gastroenteritis or 
rotavirus by the number of children < 5 years of age in participating states, according to the 
National Center for Health Statistics’ bridged-race post-censal population estimates [15]. ED 
visit rates were calculated by month of year, age group, sex, and race. ED visit rates were 
also characterized by rotavirus season, defined as the months from January-June of all years 
as has been done for other analyses using laboratory and hospital discharge data [6, 8, 16, 
17].
To compare the relative difference in pre- and post-vaccine years, gastroenteritis- and 
rotavirus-coded ED visit rates for pre-vaccine years 2003–2006 were compared with the 
post-vaccine rates in every year from 2008–2013. Data from 2007 were excluded because 
rotavirus vaccine uptake was low and uneven during the first year after vaccine introduction. 
Rate ratios with 95% confidence intervals were calculated using Poisson regression analysis. 
Statistical significance was defined as a 2-sided P value of <0.05. SAS version 9.3 (SAS 
Institute Inc) was used for all analyses.
This analysis was conducted as a collaboration between CDC and AHRQ. As all analyses 
were completed with aggregated and de-identified ED discharge records and no human 
subjects were involved, informed consent and bioethical review were not required.
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A total of 1,450,474 ED visits coded for gastroenteritis and 13,350 ED visits coded for 
rotavirus occurred in children <5 years of age in the 10 states from 2003–2013. Overall 
gastroenteritis-coded ED visits decreased significantly by 10.3% (±0.3%, p<.0001) in the six 
post-vaccine years (2008–2013) compared with the pre-vaccine years (2003–2006). ED 
visits were significantly reduced in 5 of the 6 post-vaccine years compared to the pre-
vaccine period, with the largest decline of 20.4% (±0.5%, p<.0001) seen in 2012 (Table). 
Declines were similar among male and female children. By age group, there was a greater 
reduction in ED visits in age groups less than 2 years old (from 14.1%–20.6%, p<.0001), 
while visits remained unchanged or increased for children 2–5 years old. Hispanic children 
experienced a larger reduction in ED visits (23.1% ±1.0%) than White (13.7% ±0.5%) or 
Black (13.1% ±0.6%) children (p<.0001 for all comparisons).
The declines in ED visits were restricted to the months of the year from January to June 
during which rotavirus circulates in US Children, with a 21.2% (±0.4%, p<.0001) reduction 
in ED visits during these months overall in children <5 years of age in the post-vaccine 
period compared with pre-vaccine years. Similar to the annual reductions, the greatest 
reduction of 37.7% (±0.6%, p<.0001) during the rotavirus season was also seen in 2012. In 
contrast to the decline in the rotavirus-season months, a 9.5% (±0.6%, p<.0001) increase in 
ED visits was seen during the non-rotavirus season months from July to December.
Monthly gastroenteritis-coded ED visits (Figure 1A) decreased notably during rotavirus 
seasons in post-vaccine years relative to pre-vaccine years. The reductions in all-cause 
gastroenteritis ED visits mirrored the decline in ED visits assigned the rotavirus-specific 
code (Figure 1B), and, as expected, more prominent declines were seen in rotavirus-specific 
ED visits.
The largest and most consistent reductions in ED visits for gastroenteritis were in children 
<23 months of age (Figure 2).
Conclusions
Since the introduction of rotavirus vaccination in 2006, emergency department visits for all-
cause acute gastroenteritis in children <5 years of age have declined through December 
2013. The reduction in ED utilization has occurred primarily from January-June, the months 
when rotavirus infection is most common, and in children <2 years of age, the age group 
that is most likely to experience rotavirus infection [2]. These findings suggest strongly that 
the reduction in ED visits for gastroenteritis is likely attributable to rotavirus vaccination, as 
opposed to unmeasured contemporaneous factors or changes in coding practices.
Our results are consistent with and expand on results from prior studies showing a reduction 
in rotavirus detection, hospitalization, and resource utilization since vaccine introduction [3–
6, 10, 17–20]. The most direct comparison can be made with an analysis of ED utilization 
using the 2001–2011 Truven Health MarketScan Commercial Claims and Encounters 
Database, an insurance claims database that is largely from large, self-insured companies, 
and excludes Medicaid recipients and the uninsured [5]. This analysis showed reductions in 
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ED visits for gastroenteritis from −2 to 31% in the first five years following rotavirus 
vaccine introduction from 2007–2011, and a smaller decrease in -1 to 20% in outpatient 
(non-ED) visits for gastroenteritis in the same time period.
The change in ED visits for gastroenteritis (ranging from an increase of 1.8% to a decrease 
of 20.4% in individual years from 2008–2013) is not as dramatic as the change in 
hospitalizations (decreases from 31–55% in individual years from 2008–2012), using similar 
methods and a similar dataset [4]. There are at least two possible explanations for this 
finding. First, childhood gastroenteritis caused by rotavirus infection is more severe than that 
from other causes [21–23]; thus, the proportion of hospitalized diarrhea cases that are caused 
by rotavirus and thus are potentially vaccine preventable is greater than the proportion of 
diarrhea cases seen in ED settings. Second, the efficacy of rotavirus vaccines is greater 
against more severe rotavirus gastroenteritis [24–28], and thus vaccines would avert a 
greater proportion of rotavirus hospitalizations than ED visits.
Because laboratory testing for rotavirus is infrequently conducted among diarrhea patients 
seen in ED settings, our analysis focused on the less specific disease outcome of all-cause 
acute gastroenteritis. Despite the under-reporting for rotavirus in ED settings, it is reassuring 
that ED visits for rotavirus and all-cause gastroenteritis show matching reductions since 
vaccine introduction and matching post-vaccination biennial peaks, likely due to incomplete 
vaccine coverage.
Given the ecologic design our study, our examination of disease trends is potentially 
susceptible to bias from secular changes in the number of diarrhea-associated ED visits 
caused by pathogens other than rotavirus. In particular, secular trends associated with the 
emergence of new viral strains are well recognized for norovirus [29], which has emerged to 
become the leading cause of diarrhea hospitalization in US children following the decline in 
rotavirus after vaccine implementation [30]. In this regard, it is worth noting that the 
increase in ED visits seen in 2012–2013 temporally correspond to the emergence of the 
norovirus outbreak strain GII.4 Sydney [29].
In summary, our results contribute to the growing evidence of the impact of rotavirus 
vaccination in reducing the burden and severity of gastroenteritis and reducing utilization at 
multiple levels of the healthcare system in the United States. While rotavirus vaccination 
reduced ED visits more modestly than has been cited for hospitalizations, it still offers a 
valuable tool in reducing ED congestion, particularly in winter months. Increasing rotavirus 
vaccine coverage in eligible children remains a public health priority to sustain the declines 
in the burden of severe gastroenteritis in US children.
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A. Monthly Acute Gastroenteritis-Coded Emergency Department Visits Among Children 
Younger than 5 Years in 10 States During January 2003 Through December 2013
B. Monthly Rotavirus-Coded Emergency Department Visits Among Children Younger than 
5 Years in 10 States During January 2003 Through December 2013
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Monthly Acute Gastroenteritis-Coded Emergency Department Visits for Children < 23 
months and 24–59 months of age in 10 States During January 2003 Through December 
2013
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